Research programme: tumour imaging - GE Healthcare

Drug Profile

Research programme: tumour imaging - GE Healthcare

Latest Information Update: 28 Mar 2006

Price : $50

At a glance

  • Originator GE Healthcare
  • Developer Oxford BioMedica
  • Class Radiopharmaceutical diagnostics
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 Mar 2006 No development reported - Preclinical for Solid tumour diagnosis in United Kingdom (unspecified route)
  • 16 Apr 2004 Amersham has merged with GE Medical Systems to form GE Healthcare
  • 04 May 2000 Preclinical development for Solid tumour diagnosis in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top